Sarah Gaffey

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla et al. · Nature Medicine · 2019 · 1.3K citations

Neuro-oncology, Neoadjuvant Anti-pd-1 Immunotherapy, Tumor Immunology +14

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters et al. · Clinical Cancer Research · 2020 · 238 citations · Full text

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Patrick Y. Wen, Mehdi Touat, Brian M. Alexander et al. · Journal of Clinical Oncology · 2019 · 146 citations · Full text

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

E. Q. Lee, David A. Reardon, D. Schiff et al. · Neuro-Oncology · 2015 · 129 citations · Full text

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Andrew D. Norden, Keith L. Ligon, Samantha N. Hammond et al. · Neurology · 2014 · 115 citations · Full text